Navigation Links
Light Sciences Oncology Appoints David P. Holveck to Its Board of Directors
Date:4/7/2008

BELLEVUE, Wash., April 7, 2008 /PRNewswire/ -- Light Sciences Oncology, Inc. (LSO) today announced the appointment of David P. Holveck to its Board of Directors. The appointment increases Board membership to eight.

Holveck, 62, is the President, Chief Executive Officer and a Director of Endo Pharmaceuticals. He is the former President of Johnson & Johnson Development Corp. and a Vice President of Corporate Development with Johnson & Johnson (NYSE: JNJ). Previously, he was President and Chief Executive Officer of Centocor Inc. until its acquisition by Johnson & Johnson in 1999. Prior to joining Centocor, he had held positions at General Electric Company, Corning Glass Works and Abbott Laboratories.

"I am pleased and excited to welcome Dave Holveck to our Board," said Llew Keltner, LSO's President and Chief Executive Officer. "He will be a tremendous asset to our company, especially at such an important time in the company's evolution as we reach key milestones in the late-stage development of our light-activated drug therapy."

"Joining the LSO board is a great opportunity to help guide this dynamic company in its future growth and accomplishment," added Holveck. "Together with the other board members, I hope to ensure that the company's potentially revolutionary therapy finds the best possible pathway into medical practice."

Holveck is a member of the Board of Trustees for The Fund for West Chester University, the Board of Directors of the Eastern Technology Council and Cleveland Clinic's Industrial Advisory Board. He has served as a board member of the Pharmaceutical Research and Manufacturing Association (PhRMA) and the Biotechnology Industry Organization (BIO).

He received a Bachelor of Science degree in education/science from West Chester University.

ABOUT LIGHT SCIENCES ONCOLOGY

Light Sciences Oncology, Inc. (LSO) is developing Light Infusion Therapy(TM) (Litx(TM)), an innovative light-activated drug treatment for solid tumors, to provide safer and more effective treatment to cancer patients. In addition to the Phase III trials underway in hepatocellular carcinoma and colorectal cancer metastatic to the liver, the Company has completed a Phase II clinical trial of Litx in glioma. LSO has widened the scope of potential therapeutic applications for Litx to include benign neoplasms such as benign prostatic hyperplasia (BPH) and uterine fibroids, as well as vascular disease, dermatology, and all other applications of the versatile Litx platform. The Company has positioned itself for growth with a strong portfolio of intellectual property, innovative applications in development, and an exceptionally talented team.

CONTACTS

Robert M. Littauer

Vice President, Chief Financial Officer and Treasurer

425-957-8900

bobl@lsoncology.com

Llew Keltner, M.D., Ph.D.

President and CEO

425-957-8900

dr_llew@lsoncology.com

website: http://www.lsoncology.com

Light Infusion Therapy(TM) and Litx(TM) are trademarks of Light Sciences Oncology, Inc.


'/>"/>
SOURCE Light Sciences Oncology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
3. Safety Profile of TAXUS(R) Liberte(TM) Stent System Highlighted in Worlds Largest Stent Registry
4. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
5. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
6. Access Highlighted in Recent BusinessWeek Article
7. Lighting the Onco-Pipeline, Stem Cell Cancer, and More at Global Cancer Congress, January 28-29, 2008, Tampa
8. Highlights of Economic and Business Growth in the Tampa Bay Region
9. Respironics Acquires Apollo Light Systems, Inc., Expands into Circadian Rhythm Device-Based Therapy Market
10. Americas Heartland Launches Third Season Highlighting Contributions of American Farmers and Ranchers
11. CU researchers shed light on light-emitting nanodevice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
(Date:6/23/2016)... -- On Wednesday, June 22, 2016, the NASDAQ ... Dow Jones Industrial Average edged 0.27% lower to finish at ... Stock-Callers.com has initiated coverage on the following equities: Infinity Pharmaceuticals ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ... Learn more about these stocks by accessing their free trade ...
(Date:6/23/2016)... Connecticut (PRWEB) , ... June 23, 2016 , ... ... introduce a new line of intelligent tools designed, tuned and optimized exclusively for ... September 12–17 in Chicago. The result of a collaboration among several companies with ...
(Date:6/22/2016)... , June 22, 2016 Cell Applications, ... allow them to produce up to one billion ... lot within one week. These high-quality, consistent stem ... preparing cells and spend more time doing meaningful, ... a proprietary, high-volume manufacturing process that produces affordable, ...
Breaking Biology Technology:
(Date:6/15/2016)... , June 15, 2016 ... report titled "Gesture Recognition Market by Application Market - Global Industry ... - 2024". According to the report, the  global gesture ... in 2015 and is estimated to grow at ... billion by 2024.  Increasing application of ...
(Date:6/2/2016)... The Department of Transport Management (DOTM) ... million US Dollar project, for the , Supply ... Enrolment, and IT Infrastructure , to ... implementation of Identity Management Solutions. Numerous renowned international vendors participated ... was selected for the most compliant and innovative ...
(Date:5/20/2016)... -- VoiceIt is excited to announce its new marketing ... working together, VoiceIt and VoicePass will offer an ... slightly different approaches to voice biometrics, collaboration between ... Both companies ... "This marketing and technology partnership allows VoiceIt ...
Breaking Biology News(10 mins):